DevCurationThe Premier Voice of the Entire Tech Ecosystem
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Latest
BluesightBluesight|Crosslink CapitalCrosslink Capital|Blackstone Closes $6.3B Life Sciences Fund at Hard Cap to Back Late-Stage Healthcare InnovationBlackstone Closes $6.3B Life Sciences Fund at Hard Cap to Back Late-Stage Healthcare Innovation|Sycamore Raises $65M Seed to Build the Operating System for Enterprise AI AgentsSycamore Raises $65M Seed to Build the Operating System for Enterprise AI Agents|Physical Intelligence Nears $1B Raise at $11B+ Valuation to Build General-Purpose Robot AIPhysical Intelligence Nears $1B Raise at $11B+ Valuation to Build General-Purpose Robot AI|Insilico Medicine Signs $2.75B AI Drug Discovery Deal with Eli LillyInsilico Medicine Signs $2.75B AI Drug Discovery Deal with Eli Lilly|Sysco Acquires Jetro Restaurant Depot for $29.1B to Enter Cash & Carry SegmentSysco Acquires Jetro Restaurant Depot for $29.1B to Enter Cash & Carry Segment|ScaleOps Raises $130M Series C to Automate Cloud and AI Infrastructure ManagementScaleOps Raises $130M Series C to Automate Cloud and AI Infrastructure Management|Qodo Raises $70M Series B to Build Trust Layer for AI-Generated CodeQodo Raises $70M Series B to Build Trust Layer for AI-Generated Code|Rivian Secures Additional $1B Investment from Volkswagen to Expand EV Platform and SoftwareRivian Secures Additional $1B Investment from Volkswagen to Expand EV Platform and Software|BluesightBluesight|Crosslink CapitalCrosslink Capital|Blackstone Closes $6.3B Life Sciences Fund at Hard Cap to Back Late-Stage Healthcare InnovationBlackstone Closes $6.3B Life Sciences Fund at Hard Cap to Back Late-Stage Healthcare Innovation|Sycamore Raises $65M Seed to Build the Operating System for Enterprise AI AgentsSycamore Raises $65M Seed to Build the Operating System for Enterprise AI Agents|Physical Intelligence Nears $1B Raise at $11B+ Valuation to Build General-Purpose Robot AIPhysical Intelligence Nears $1B Raise at $11B+ Valuation to Build General-Purpose Robot AI|Insilico Medicine Signs $2.75B AI Drug Discovery Deal with Eli LillyInsilico Medicine Signs $2.75B AI Drug Discovery Deal with Eli Lilly|Sysco Acquires Jetro Restaurant Depot for $29.1B to Enter Cash & Carry SegmentSysco Acquires Jetro Restaurant Depot for $29.1B to Enter Cash & Carry Segment|ScaleOps Raises $130M Series C to Automate Cloud and AI Infrastructure ManagementScaleOps Raises $130M Series C to Automate Cloud and AI Infrastructure Management|Qodo Raises $70M Series B to Build Trust Layer for AI-Generated CodeQodo Raises $70M Series B to Build Trust Layer for AI-Generated Code|Rivian Secures Additional $1B Investment from Volkswagen to Expand EV Platform and SoftwareRivian Secures Additional $1B Investment from Volkswagen to Expand EV Platform and Software
DevCuration

Ecosystem intelligence for operators, investors, and builders navigating the tech landscape.

Explore

  • Where the Money Moved
  • Events
  • Articles & Analysis

Spotlights

  • Investor Spotlight
  • Company Spotlight
  • Frameworks

Company

  • About Us
  • Privacy Policy
  • Terms of Service
© 2026 DevCuration. All rights reserved.
TwitterLinkedIn
Back to articles
March 30, 2026
•Jesse Landry

BlueMatrix

Some layers in capital markets never make headlines, but they decide who does. Not the trade. Not the model. The system behind the scenes that determines how research is written, approved, governed, and delivered before capital ever moves. BlueMatrix has owned that layer since 1999, long before most firms realized how exposed that process really was.

Patricia Horotan and Skye Hauptman did not start with hype. They started with a problem that could get firms fined, burned, or ignored. Research workflows were manual, fragmented, and risky. So they built a web based system that institutionalized discipline. Over the next 2 decades, Patricia Horotan turned that early conviction into infrastructure trusted by more than 1,000 financial institutions, connecting nearly 1,000 research firms across more than 50 countries. Quiet dominance. The kind that compounds.

Now the tempo shifts. March 2026 brings David Nable into the CEO role, with Patricia Horotan stepping into CSO. This is not a cosmetic move. It is a signal. BlueMatrix is leaning into its next act as the control layer for machine-assisted research workflows, where attribution, permissions, and compliance are not features, they are the price of entry.

Some platforms rush to add intelligence on top. Others are forced to clean up the mess after. BlueMatrix is taking a different route, reinforcing the system where research is created and controlled so that any machine interacting with it operates inside clear boundaries. Their platform already owns the authoring, approval, entitlement, and distribution chain. Now it is extending that same control into how research is accessed, interpreted, and distributed at scale.

Backing matters here. Thoma Bravo stepped in with a strategic investment completed in early 2024, adding operational muscle to a company that already had deep roots. Then came the 2025 acquisition of FactSet’s RMS business, expanding reach and tightening its grip across both buy side and sell side workflows. This is how infrastructure companies widen the moat without making noise.

Inside the company, the work reflects the stakes. Engineers operate in a world where Java, distributed systems, and performance tuning meet regulatory scrutiny. Teams span Durham, New York, London, Edinburgh, Auckland, and Timisoara, mirroring a client base that never sleeps. This is not casual software. This is systems that institutions depend on when the margin for error is zero.

BlueMatrix is hiring across engineering, cloud, and go to market roles, building toward a future where research systems and machine driven workflows operate with precision and control. If you are building in capital markets or data infrastructure, this is a company worth studying closely, or better yet, stepping into while the next chapter is still being written.

Back to all articles
View Career Page

Related Articles

Company Spotlight
Bluesight
Mar 31, 2026
Company Spotlight
Azul
Mar 29, 2026
Company Spotlight
Archetype AI
Mar 28, 2026
Company Spotlight
Vertex Pharmaceuticals
Mar 27, 2026
Company Spotlight
Pearl
Mar 26, 2026

More from Jesse Landry

Investor Spotlight
Crosslink Capital
Mar 31, 2026
Where the Money Moved
Blackstone Closes $6.3B Life Sciences Fund at Hard Cap to Back Late-Stage Healthcare Innovation
Mar 31, 2026

Trending

Events
BetterFutureLabs and TechUnited:NJ Demand Proof: AI Demo Night #10
Mar 27, 2026
Frameworks
The Provenance Problem — Why AI Governance Is Collapsing Into Proof of Human Control
Mar 26, 2026
View all posts